Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Tumor Biology
Published in: Tumor Biology 8/2016

01-08-2016 | Original Article

Isoform 1 of TPD52 (PC-1) promotes neuroendocrine transdifferentiation in prostate cancer cells

Authors: Tom Moritz, Simone Venz, Heike Junker, Sarah Kreuz, Reinhard Walther, Uwe Zimmermann

Published in: Tumor Biology | Issue 8/2016

Login to get access

Abstract

The tumour protein D52 isoform 1 (PC-1), a member of the tumour protein D52 (TPD52) protein family, is androgen-regulated and prostate-specific expressed. Previous studies confirmed that PC-1 contributes to malignant progression in prostate cancer with an important role in castration-resistant stage. In the present work, we identified its impact in mechanisms leading to neuroendocrine (NE) transdifferentiation. We established for long-term PC-1 overexpression an inducible expression system derived from the prostate carcinoma cell line LNCaP. We observed that PC-1 overexpression itself initiates characteristics of neuroendocrine cells, but the effect was much more pronounced in the presence of the cytokine interleukin-6 (IL-6). Moreover, to our knowledge, this is the first report that treatment with IL-6 leads to a significant upregulation of PC-1 in LNCaP cells. Other TPD52 isoforms were not affected. Proceeding from this result, we conclude that PC-1 overexpression enhances the IL-6-mediated differentiation of LNCaP cells into a NE-like phenotype, noticeable by morphological changes and increased expression of typical NE markers, like chromogranin A, synaptophysin or beta-3 tubulin. Immunofluorescent staining of IL-6-treated PC-1-overexpressing LNCaP cells indicates a considerable PC-1 accumulation at the end of the long-branched neuron-like cell processes, which are typically formed by NE cells. Additionally, the experimentally initiated NE transdifferentiation correlates with the androgen receptor status, which was upregulated additively. In summary, our data provide evidence for an involvement of PC-1 in NE transdifferentiation, frequently associated with castration resistance, which is a major therapeutic challenge in the treatment of advanced prostate cancer.
Literature
1.
2.
Byrne JA, Mattei MG, Basset P. Definition of the tumor protein D52 (TPD52) gene family through cloning of D52 homologues in human (hD53) and mouse (mD52). Genomics. 1996;35(3):523–32.CrossRefPubMed
3.
Byrne JA, et al. Identification of homo- and heteromeric interactions between members of the breast carcinoma-associated D52 protein family using the yeast two-hybrid system. Oncogene. 1998;16(7):873–81.CrossRefPubMed
4.
Byrne JA, et al. A screening method to identify genes commonly overexpressed in carcinomas and the identification of a novel complementary DNA sequence. Cancer Res. 1995;55(13):2896–903.PubMed
5.
Visakorpi T, et al. Genetic changes in primary and recurrent prostate cancer by comparative genomic hybridization. Cancer Res. 1995;55(2):342–7.PubMed
6.
Wang R, et al. Transcription variants of the prostate-specific PrLZ gene and their interaction with 14-3-3 proteins. Biochem Biophys Res Commun. 2009;389(3):455–60.CrossRefPubMedPubMedCentral
7.
Chen SL, et al. Isolation and characterization of a novel gene expressed in multiple cancers. Oncogene. 1996;12(4):741–51.PubMed
8.
Wang R, et al. PrLZ, a novel prostate-specific and androgen-responsive gene of the TPD52 family, amplified in chromosome 8q21.1 and overexpressed in human prostate cancer. Cancer Res. 2004;64(5):1589–94.CrossRefPubMed
9.
Zhang H, et al. PC-1/PrLZ contributes to malignant progression in prostate cancer. Cancer Res. 2007;67(18):8906–13.CrossRefPubMed
10.
Thomas DD, et al. A role for tumor protein TPD52 phosphorylation in endo-membrane trafficking during cytokinesis. Biochem Biophys Res Commun. 2010;402(4):583–7.CrossRefPubMedPubMedCentral
11.
Thomas DD, et al. CRHSP-28 regulates Ca(2+)-stimulated secretion in permeabilized acinar cells. J Biol Chem. 2001;276(31):28866–72.CrossRefPubMed
12.
Thomas DD, Weng N, Groblewski GE. Secretagogue-induced translocation of CRHSP-28 within an early apical endosomal compartment in acinar cells. Am J Physiol Gastrointest Liver Physiol. 2004;287(1):G253–63.CrossRefPubMed
13.
Ummanni R, et al. Altered expression of tumor protein D52 regulates apoptosis and migration of prostate cancer cells. FEBS J. 2008;275(22):5703–13.CrossRefPubMed
14.
Li L, et al. Increased PrLZ-mediated androgen receptor transactivation promotes prostate cancer growth at castration-resistant stage. Carcinogenesis. 2013;34(2):257–67.CrossRefPubMed
15.
16.
17.
Lee YF, et al. Activation of mitogen-activated protein kinase pathway by the antiandrogen hydroxyflutamide in androgen receptor-negative prostate cancer cells. Cancer Res. 2002;62(21):6039–44.PubMed
18.
Montgomery RB, et al. Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth. Cancer Res. 2008;68(11):4447–54.CrossRefPubMedPubMedCentral
19.
Huss WJ, Gregory CW, Smith GJ. Neuroendocrine cell differentiation in the CWR22 human prostate cancer xenograft: association with tumor cell proliferation prior to recurrence. Prostate. 2004;60(2):91–7.CrossRefPubMed
20.
Jin RJ, et al. NE-10 neuroendocrine cancer promotes the LNCaP xenograft growth in castrated mice. Cancer Res. 2004;64(15):5489–95.CrossRefPubMed
21.
Bonkhoff H. Neuroendocrine cells in benign and malignant prostate tissue: morphogenesis, proliferation, and androgen receptor status. Prostate Suppl. 1998;8:18–22.CrossRefPubMed
22.
Abrahamsson PA. Neuroendocrine cells in tumour growth of the prostate. Endocr Relat Cancer. 1999;6(4):503–19.CrossRefPubMed
23.
Abrahamsson PA. Neuroendocrine differentiation in prostatic carcinoma. Prostate. 1999;39(2):135–48.CrossRefPubMed
24.
di Sant'Agnese PA, Cockett AT. Neuroendocrine differentiation in prostatic malignancy. Cancer. 1996;78(2):357–61.CrossRefPubMed
25.
Corcoran NM, Costello AJ. Interleukin-6: minor player or starring role in the development of hormone-refractory prostate cancer? BJU Int. 2003;91(6):545–53.CrossRefPubMed
26.
Drachenberg DE, et al. Circulating levels of interleukin-6 in patients with hormone refractory prostate cancer. Prostate. 1999;41(2):127–33.CrossRefPubMed
27.
Nakashima J, et al. Serum interleukin 6 as a prognostic factor in patients with prostate cancer. Clin Cancer Res. 2000;6(7):2702–6.PubMed
28.
Deeble PD, et al. Interleukin-6- and cyclic AMP-mediated signaling potentiates neuroendocrine differentiation of LNCaP prostate tumor cells. Mol Cell Biol. 2001;21(24):8471–82.CrossRefPubMedPubMedCentral
29.
Mori R, et al. Gene profiling and pathway analysis of neuroendocrine transdifferentiated prostate cancer cells. Prostate. 2009;69(1):12–23.CrossRefPubMed
30.
Hirano D, et al. Neuroendocrine differentiation in hormone refractory prostate cancer following androgen deprivation therapy. Eur Urol. 2004;45(5):586–92. discussion 592.CrossRefPubMed
31.
Miyamoto H, Messing EM, Chang C. Androgen deprivation therapy for prostate cancer: current status and future prospects. Prostate. 2004;61(4):332–53.CrossRefPubMed
32.
Lottmann H, et al. The Tet-On system in transgenic mice: inhibition of the mouse pdx-1 gene activity by antisense RNA expression in pancreatic beta-cells. J Mol Med (Berl). 2001;79(5–6):321–8.CrossRef
33.
Gossen M, Bujard H. Tight control of gene expression in mammalian cells by tetracycline-responsive promoters. Proc Natl Acad Sci U S A. 1992;89(12):5547–51.CrossRefPubMedPubMedCentral
34.
Li L, et al. PrLZ expression is associated with the progression of prostate cancer LNCaP cells. Mol Carcinog. 2009;48(5):432–40.CrossRefPubMed
35.
Ge D, et al. LNCaP prostate cancer cells with autocrine interleukin-6 expression are resistant to IL-6-induced neuroendocrine differentiation due to increased expression of suppressors of cytokine signaling. Prostate. 2012;72(12):1306–16.CrossRefPubMed
36.
Marchiani S, et al. Androgen-responsive and -unresponsive prostate cancer cell lines respond differently to stimuli inducing neuroendocrine differentiation. Int J Androl. 2010;33(6):784–93.CrossRefPubMed
37.
Zelivianski S, et al. Multipathways for transdifferentiation of human prostate cancer cells into neuroendocrine-like phenotype. Biochim Biophys Acta. 2001;1539(1–2):28–43.CrossRefPubMed
38.
Lee SO, et al. Interleukin-6 undergoes transition from growth inhibitor associated with neuroendocrine differentiation to stimulator accompanied by androgen receptor activation during LNCaP prostate cancer cell progression. Prostate. 2007;67(7):764–73.CrossRefPubMed
39.
Hobisch A, et al. Interleukin-6 regulates prostate-specific protein expression in prostate carcinoma cells by activation of the androgen receptor. Cancer Res. 1998;58(20):4640–5.PubMed
40.
Wang J, et al. Identification and characterization of the novel human prostate cancer-specific PC-1 gene promoter. Biochem Biophys Res Commun. 2007;357(1):8–13.CrossRefPubMed
41.
Zhang D, et al. PrLZ protects prostate cancer cells from apoptosis induced by androgen deprivation via the activation of Stat3/Bcl-2 pathway. Cancer Res. 2011;71(6):2193–202.CrossRefPubMedPubMedCentral
42.
Bonkhoff H, et al. Relation of endocrine-paracrine cells to cell proliferation in normal, hyperplastic, and neoplastic human prostate. Prostate. 1991;19(2):91–8.CrossRefPubMed
Metadata
Title
Isoform 1 of TPD52 (PC-1) promotes neuroendocrine transdifferentiation in prostate cancer cells
Authors
Tom Moritz
Simone Venz
Heike Junker
Sarah Kreuz
Reinhard Walther
Uwe Zimmermann
Publication date
01-08-2016
Publisher
Springer Netherlands
Published in
Tumor Biology / Issue 8/2016
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-016-4925-1

Other articles of this Issue 8/2016

Tumor Biology 8/2016 Go to the issue

Original Article

The interaction of hepatoma-derived growth factor and β-catenin promotes tumorigenesis of synovial sarcoma

Original Article

Clinical characteristics and prognostic indicators for metastatic melanoma: data from 446 patients in north China

Original Article

PCA3 long noncoding RNA modulates the expression of key cancer-related genes in LNCaP prostate cancer cells

Original Article

Enzymatically active cathepsin D sensitizes breast carcinoma cells to TRAIL

Original Article

Colchicine induces autophagy and senescence in lung cancer cells at clinically admissible concentration: potential use of colchicine in combination with autophagy inhibitor in cancer therapy

Original Article

Association between the CpG island methylator phenotype and its prognostic significance in primary pulmonary adenocarcinoma
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits